Wellington Management Group
ECYT

Wellington Management Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Wellington Management Group’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-83,000
Closed -$1.15M – 2386
2018
Q2 		$1.15M Buy
+83,000
New +$985K ﹤0.01% 1855
2013
Q3 		– Sell
-115,145
Closed -$1.51M – 2261
2013
Q2 		$1.51M Buy
+115,145
New +$1.55M ﹤0.01% 1686

Other funds holding ECYT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group's ECYT Position: Q3 2018 in Review

Wellington Management Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2018, closing a stake of 83,000 shares — an estimated $1.15M sold.

Wellington Management Group first reported a position in ECYT in Q2 2013 and held it in 2 quarters. The position peaked at $1.51M in Q2 2013. 139 funds tracked by Wall St. Rank hold ECYT as of Q3 2018.

  • Wellington Management Group reported no remaining Endocyte, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Wellington Management Group sold 83,000 Endocyte, Inc. Common Stock shares in Q3 2018, an estimated $1.15M.
  • Wellington Management Group first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • Wellington Management Group's Endocyte, Inc. Common Stock position peaked at $1.51M in Q2 2013.
  • 139 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2018.

Based on Wellington Management Group's 13F filing for Q3 2018, filed 14 Nov 2018.